Brim Biotechnology submitted an investigational new drug application to the FDA for BRM424 for the treatment of neurotrophic keratitis, according to a press release.
If the FDA does not comment within 30 days, the company plans to initiate a phase 2 study to investigate BRM424 in the first half of the year.
“This regenerative peptide has neurotrophic properties, and its mechanism of action is based on its ability to stimulate limbal stem cell regeneration,” Wen Chyi Shyu, PhD, CEO of Brim, said in the release. “Therefore, it can rapidly repair (Read more...)